Immune checkpoint inhibitors (ICIs) targeting programmed cell death receptor 1 (PD-1) and its ligand (PD-L1) including pembrolizumab, atezolizumab, and nivolumab are now the standard of care for the first-line management of patients with metastatic NSCLC with or without chemotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.